Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412631 · ClinicalTrials.gov registry record · Phase 2
Addressing Post Cessation Weight Gain
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT02412631: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT02412631 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02412631, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
Some individuals smoke with the perception that smoking helps control body weight. Smokers gain an average of as much as 10 pounds in the months following smoking abstinence, with heavier and more-dependent smokers gaining more weight. T The Mayo Clinic Nicotine Research Program will randomize 100 nondiabetic, overweight or obese adult smokers to active lorcaserin or placebo for 24 weeks; all of the subjects will receive open-label varenicline for 12 weeks. The purpose of this study is to assess the efficacy of a 24-week course of lorcaserin for decreasing weight gain after stopping smoking.
Interventions
- DRUG Placebo
- DRUG Varenicline
- DRUG lorcaserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2016-06-15 |
| Est. Completion | 2020-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02412631
The ClinicalTrials.gov registry entry for NCT02412631 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02412631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02412631 about?
NCT02412631 is a clinical study titled "Addressing Post Cessation Weight Gain". Some individuals smoke with the perception that smoking helps control body weight. Smokers gain an average of as much as 10 pounds in the months following smoking abstinence, with heavier and more-dependent smokers gaining more weight. T The Mayo Clinic Nicotine Research Program will randomize 100 n...
What is the current status of trial NCT02412631?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2016-06-15. Estimated completion is 2020-04-17.
What interventions are being tested in trial NCT02412631?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), lorcaserin (DRUG).
Who is sponsoring clinical trial NCT02412631?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.